We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

200 hedge funds and large institutions have $589M invested in Immunogen Inc in 2018 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 65 increasing their positions, 56 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

434% more call options, than puts

Call options by funds: $18.7M | Put options by funds: $3.49M

16% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 56

4% less funds holding

Funds holding: 208200 (-8)

16% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 45

50% less capital invested

Capital invested by funds: $1.18B → $589M (-$592M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
200
Holders Change
-8
Holders Change %
-3.85%
% of All Funds
4.46%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
38
Increased
65
Reduced
56
Closed
45
Calls
$18.7M
Puts
$3.49M
Net Calls
+$15.2M
Net Calls Change
+$529K
Name Holding Trade Value Shares
Change
Change in
Stake
Los Angeles Capital Management
76
Los Angeles Capital Management
California
$374K -$4.7K -775 -1%
State Board of Administration of Florida Retirement System
77
State Board of Administration of Florida Retirement System
Florida
$372K
William Blair & Company
78
William Blair & Company
Illinois
$366K +$397K +65,473 New
QSS
79
Quantitative Systematic Strategies
Florida
$353K +$374K +61,686 +523%
Jane Street
80
Jane Street
New York
$340K +$351K +57,865 +450%
AQR Capital Management
81
AQR Capital Management
Connecticut
$336K -$9.05K -1,491 -2%
N
82
Nuveen
North Carolina
$332K
GC
83
Grace Capital
Massachusetts
$329K +$176K +29,000 +73%
BTS
84
BB&T Securities
Virginia
$325K -$2.35K -388 -0.6%
MSL
85
Mackay Shields LLC
New York
$317K +$62.6K +10,310 +18%
ProShare Advisors
86
ProShare Advisors
Maryland
$315K -$76.9K -12,673 -16%
QIM
87
Quantitative Investment Management
Virginia
$312K +$394K +65,000 New
TD Asset Management
88
TD Asset Management
Ontario, Canada
$306K
Barclays
89
Barclays
United Kingdom
$300K -$82.8K -13,653 -18%
MIM
90
MetLife Investment Management
New Jersey
$287K
VEA
91
Virtus ETF Advisers
New York
$273K +$71.4K +11,759 +26%
GCP
92
GSA Capital Partners
United Kingdom
$273K +$345K +56,800 New
Axa
93
Axa
France
$268K +$339K +55,844 New
AIM
94
Assured Investment Management
New York
$265K +$181K +29,864 +118%
Envestnet Asset Management
95
Envestnet Asset Management
Illinois
$242K +$306K +50,488 New
MLICM
96
Metropolitan Life Insurance Company (MetLife)
New York
$226K
Nisa Investment Advisors
97
Nisa Investment Advisors
Missouri
$217K +$270K +44,565 +6,063%
DekaBank Deutsche Girozentrale
98
DekaBank Deutsche Girozentrale
Germany
$201K -$60.7K -10,000 -18%
CSS
99
Cubist Systematic Strategies
Connecticut
$190K +$205K +33,850 +582%
JP Morgan Chase
100
JP Morgan Chase
New York
$189K +$22.1K +3,644 +10%

IMGN Hedge Fund Activity: Q4 2018 in Review

200 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q4 2018, worth a combined $589M — down 50% from $1.18B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of IMGN and 38 opened new positions — a net loss of 7 holders — while 56 trimmed existing stakes and 65 added.

The largest buyer was Millennium Management, adding an estimated $21.6M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $67.2M sold.

  • 200 institutional investors held Immunogen Inc (IMGN) as of Q4 2018, down from 208 in Q3 2018.
  • Funds reported $589M of Immunogen Inc stock for Q4 2018, down 50% quarter-over-quarter.
  • 38 funds opened new Immunogen Inc positions in Q4 2018 and 45 closed out, a net change of -7 holders.
  • The largest Immunogen Inc buyer in Q4 2018 was Millennium Management, an estimated $21.6M added.
  • The largest Immunogen Inc seller in Q4 2018 was Capital Research Global Investors, an estimated $67.2M sold.

Based on aggregated 13F filings for Q4 2018.